Beam Therapeutics Inc Stock

$16.80

1.98% yesterday

Nasdaq, Jun 27, 10:06 pm CET

ISIN

US07373V1052

Symbol

BEAM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Beam Therapeutics Inc Stock price

$16.80

-10.66 38.82% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.34 1.98%

ISIN

US07373V1052

Symbol

BEAM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$1.7b

Enterprise Value

$469.4m

Net debt

$-1.2b

Cash

$1.2b

Shares outstanding

100.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

26.57 | 31.74

EV/Sales

7.38 | 8.82

EV/FCF

negative

P/B

1.50

Financial Health

Equity Ratio

66.45%

Return on Equity

-51.36%

ROCE

-32.50%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$63.6m | $53.2m

EBITDA

$-408.7m | $-473.4m

EBIT

$-430.7m

Net Income

$-387.3m | $-474.7m

Free Cash Flow

$-361.0m

Growth (TTM | estimate)

Revenue

-82.38% | -16.21%

EBITDA

-154.09% | -20.27%

EBIT

-137.06%

Net Income

-187.47% | -26.00%

Free Cash Flow

-113.19%

Margin (TTM | estimate)

Gross

EBITDA

-642.83% | -889.55%

EBIT

-677.47%

Net

-609.24% | -891.90%

Free Cash Flow

-567.74%

EPS

$-4.40

FCF per Share

$-3.59

Short interest

24.30%

Employees

483.00

Rev per Employee

$130.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

23 Analysts have issued a Beam Therapeutics Inc forecast:

19x Buy

83%

4x Hold

17%

More details on Analyst Estimates Including Price Targets

23 Analysts have issued a Beam Therapeutics Inc forecast:

Buy

83%

Hold

17%

Analyst Estimates with Stock Price Targets

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	64 64	82% 82% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	113 113	6% 6% 177%
- Research and Development Expense	382 382	10% 10% 600%
EBITDA	-409 -409	154% 154% -643%
- Depreciation and Amortization	22 22	6% 6% 35%
EBIT (Operating Income) EBIT	-431 -431	137% 137% -677%
Net Profit	-387 -387	187% 187% -609%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Beam Therapeutics Inc Stock News

Positive

Schaeffers Research

●

4 days ago

Top Stock Pick Report: V-Shaped Rallies Everywhere

Back in late March, we power ranked our Top Stock Picks of 2025. There was some success and lessons to be drawn, but if we're being honest, this wasn't the entire story. There was red ink everywhere and combined with the looming threat of unilateral tariffs on ‘Liberation Day,' fear had grown surrounding a potential recession hitting by the time a second-quarter check-in came around.

Negative

Investors Business Daily

●

8 days ago

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

Positive

Seeking Alpha

●

8 days ago

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032.

More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office	United States
CEO	John Evans
Employees	483
Founded	2017
Website	beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now